- The shares of U.K.-based Akari Therapeutics ( NASDAQ: AKTX ) reached the highest level since early March on Monday after the company announced changes to its pipeline programs following a reassessment of development timelines and associated costs.
- Accordingly, Akari ( AKTX ) plans to prioritize two development programs. One will involve childen in a Phase 3 trial for its lead asset nomacopan in severe hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Part A data from that study is expected in H1 2023.
- In light of the favorable pre-clinical results, the company will also run a pre-clinical program for PAS-nomacopan in geographic atrophy (GA). However, Akari ( AKTX ) will halt further development of nomacopan for the rare skin condition bullous pemphigoid (BP).
- The reprioritization of the pipeline is not due to BP clinical data, and the move does not involve restructuring or a reduction of the headcount, Akari ( AKTX ) said.
- Read: In May, the company announced peer-reviewed publication of Phase 2 data for nomacopan in BP.
For further details see:
Akari hits over five-month high on reprioritization of pipeline